Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial
Sign Up to like & getrecommendations! Published in 2017 at "PLoS Medicine"
DOI: 10.1371/journal.pmed.1002435
Abstract: Background VRC01 is an HIV-1 CD4 binding site broadly neutralizing antibody (bnAb) that is active against a broad range of HIV-1 primary isolates in vitro and protects against simian-human immunodeficiency virus (SHIV) when delivered parenterally… read more here.
Keywords: administration; vrc01 administered; infusion; antibody ... See more keywords